Dr. Yednock recently joined the Drug Advisory Board of the Myelin Repair Foundation, a nonprofit organization focused on the discovery and development of therapeutics for multiple sclerosis (MS). Previously Dr. Yednock was the Executive Vice President and Head of Global Research for Elan Pharmaceuticals and a scientist at Athena Neurosciences. Through his scientific work at Athena, Yednock invented Tysabri (Natalizumab), a monoclonal antibody therapeutic that was approved by the FDA, in 2004, for the treatment of MS. He continued to support the program from a scientific perspective as it moved through development for MS at Elan and later in collaboration with Biogen-Idec. In addition to his work with the Myelin Repair Foundation, Yednock is also a scientific advisor to several companies and start-ups.
Yednock was an undergraduate student at the University of Illinois, Champaign-Urbana. He received his PhD in anatomy and cell biology from the University of California, San Francisco where he was also a post-doctoral fellow.
